Novotech

Novotech Appoints Dr. Yooni Kim as a New Executive Position of Managing Director for APAC to Strengthen Global Expansion

BOSTON – Novotech, the leading global biotech Contract Research Organization (CRO), is pleased to announce the appointment of Dr. Yooni Kim as a new Executive position of Managing Director for the Asia-Pacific (APAC) region, effective September 1, 2024. “We are delighted to have Dr. Yooni Kim lead our APAC region” Post this This strategic appointment is part of Novotech’s ongoing efforts to expand its global … Continue reading Novotech Appoints Dr. Yooni Kim as a New Executive Position of Managing Director for APAC to Strengthen Global Expansion

CELLINO

Cellino Awarded $25M in Funding from the Advanced Research Projects Agency for Health (ARPA-H)

Funding will Advance Cellino’s Advanced Biomanufacturing Technology for Personalized Regenerative Medicines CAMBRIDGE, Mass. – Cellino Biotech, Inc. today announced that the Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department of Health and Human Services, has awarded it up to $25 million in funding to develop an ultra-scalable, autonomous, cassette-based advanced biomanufacturing technology for personalized regenerative medicines. Cellino’s NEBULA (NExt-generation Biomanufacturing ULtra-scalable … Continue reading Cellino Awarded $25M in Funding from the Advanced Research Projects Agency for Health (ARPA-H)

Affimed

Affimed Appoints Shawn M. Leland as Chief Executive Officer

MANNHEIM, Germany, Sept. 03, 2024 (GLOBE NEWSWIRE) — Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that Shawn M. Leland, PharmD, RPh has been appointed as Chief Executive Officer (CEO). Dr. Andreas Harstrick, who has been serving as acting CEO since January 2024 will continue in his position … Continue reading Affimed Appoints Shawn M. Leland as Chief Executive Officer

AZENTA

AZENTA ANNOUNCES APPOINTMENT OF JOHN P. MAROTTA AS CEO

Succeeds Dr. Stephen Schwartz Following 14-Year Tenure BURLINGTON, Mass., Sept. 4, 2024 /PRNewswire/ — Azenta, Inc. (Nasdaq: AZTA) (“Azenta” or “the Company”), today announced that John P. Marotta will join the Company as President and CEO effective September 9, 2024, succeeding Dr. Stephen Schwartz, who is retiring following a distinguished tenure. Dr. Schwartz will remain as an advisor to Azenta to ensure a smooth and successful transition.  Mr. Marotta has two decades … Continue reading AZENTA ANNOUNCES APPOINTMENT OF JOHN P. MAROTTA AS CEO